AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS
AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021
Shots:
- AstraZeneca will divulge new developments across BC at the 2020 SABCS. The key abstract includes data of P-ll DESTINY-Breast01 study reinforcing the efficacy seen with Enhertu in HER2+ mBC following 2+ prior anti-HER2 based regimens
- The company will present data of P-I SERENA-1 study demonstrating the efficacy & safety of AZD9833 as a monothx. and in combination with the palbociclib in HR+, HER2- negative advanced BC
- AstraZeneca will present RWE to understand outcomes for patients with germline BRCA mutations and treatment patterns among patients with HER2+ mBC. The company will also showcase data on the role of AI & digital pathology in measuring levels of HER2 expression in patients with BC
Click here to read full press release/ article | Ref: AstraZeneca | Image: New Europe